Best Cytochrome P450 17A1 Inhibitor for prostatic neoplasms, castration-resistant
4 Cytochrome P450 17A1 Inhibitor drugs indicated for prostatic neoplasms, castration-resistant, ranked by our independent rating. The current highest-rated is abiraterone acetate. Compare them with all treatments for prostatic neoplasms, castration-resistant or the full Cytochrome P450 17A1 Inhibitor class. Not medical advice — always consult a professional.
Top cytochrome p450 17a1 inhibitor for prostatic neoplasms, castration-resistant: 1. Abiraterone Acetate · 2. Yonsa · 3. Akeega
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Abiraterone Acetate | 70/100 | Prescription | $26 | View → |
| 2 | Yonsa | Not yet rated | Prescription | $26 | View → |
| 3 | Akeega | Not yet rated |
Full ranking · 4 drugs
Frequently asked
- What is the best cytochrome p450 17a1 inhibitor for prostatic neoplasms, castration-resistant?
- By our independent rating, abiraterone acetate currently ranks highest among Cytochrome P450 17A1 Inhibitor drugs used for prostatic neoplasms, castration-resistant. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which cytochrome p450 17a1 inhibitor drugs treat prostatic neoplasms, castration-resistant?
- pharmaranks lists 4 Cytochrome P450 17A1 Inhibitor products indicated for prostatic neoplasms, castration-resistant, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.